BioArctic Management

Management criteria checks 4/4

BioArctic's CEO is Gunilla Osswald, appointed in Jan 2014, has a tenure of 10.33 years. total yearly compensation is SEK22.38M, comprised of 19.8% salary and 80.2% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth €1.57M. The average tenure of the management team and the board of directors is 5.3 years and 10.5 years respectively.

Key information

Gunilla Osswald

Chief executive officer

kr22.4m

Total compensation

CEO salary percentage	19.8%
CEO tenure	10.3yrs
CEO ownership	0.1%
Management average tenure	5.3yrs
Board average tenure	10.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Gunilla Osswald's remuneration changed compared to BioArctic's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	kr22m	kr4m	kr229m
Sep 30 2023	n/a	n/a	kr259m
Jun 30 2023	n/a	n/a	kr270m
Mar 31 2023	n/a	n/a	kr327m
Dec 31 2022	kr9m	kr5m	-kr11m
Sep 30 2022	n/a	n/a	kr28m
Jun 30 2022	n/a	n/a	-kr147m
Mar 31 2022	n/a	n/a	-kr135m
Dec 31 2021	kr5m	kr3m	-kr120m
Sep 30 2021	n/a	n/a	-kr114m
Jun 30 2021	n/a	n/a	-kr97m
Mar 31 2021	n/a	n/a	-kr101m
Dec 31 2020	kr5m	kr3m	-kr69m
Sep 30 2020	n/a	n/a	-kr72m
Jun 30 2020	n/a	n/a	-kr60m
Mar 31 2020	n/a	n/a	kr78m
Dec 31 2019	kr7m	kr3m	kr88m
Sep 30 2019	n/a	n/a	kr441m
Jun 30 2019	n/a	n/a	kr475m
Mar 31 2019	n/a	n/a	kr380m
Dec 31 2018	kr5m	kr3m	kr382m
Sep 30 2018	n/a	n/a	kr58m
Jun 30 2018	n/a	n/a	kr32m
Mar 31 2018	n/a	n/a	kr29m
Dec 31 2017	kr3m	kr2m	kr15m

Compensation vs Market: Gunilla's total compensation ($USD2.07M) is about average for companies of similar size in the German market ($USD1.63M).

Compensation vs Earnings: Gunilla's compensation has been consistent with company performance over the past year.

CEO

Gunilla Osswald (62 yo)

10.3yrs

Tenure

kr22,378,000

Compensation

Dr. Gunilla Osswald, PhD has been the Chief Executive Officer and President of BioArctic AB (publ) since 2014. Dr. Osswald has been a Director of Egetis Therapeutics AB (publ) (formerly known as PledPharma...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Gunilla Osswald	President & CEO	10.3yrs	kr22.38m	0.11% SEK 1.6m
Pär Gellerfors	Co-Founder	21.3yrs	kr390.00k	0% SEK 0
Lars Lannfelt	Co-Founder	21.3yrs	kr2.54m	33.43% SEK 491.1m
Anders Martin-Lof	Chief Financial Officer	less than a year	no data	no data
Johanna Fälting	Chief Research Officer & Head of Research	no data	no data	0.054% SEK 796.0k
Christer Möller	VP of Pre-Clinical Development & Chief Scientific Officer	18.3yrs	no data	0.063% SEK 927.6k
Oskar Bosson	VP and Head of IR & Communication	4yrs	no data	0.012% SEK 171.3k
Leif Gallo	General Counsel and Head of Legal & IP	no data	no data	no data
Harald Borgeke	Head of Public Affairs	2.1yrs	no data	no data
Frida Lekander	Head of Marketing	2.3yrs	no data	no data
Gunilla Andersson	Vice President of Human Resources	5.3yrs	no data	no data
Mikael Moge	VP & Head of CMC	no data	no data	0.011% SEK 155.1k

5.3yrs

Average Tenure

62yo

Average Age

Experienced Management: B9A's management team is seasoned and experienced (5.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Pär Gellerfors	Co-Founder	21.3yrs	kr390.00k	0% SEK 0
Lars Lannfelt	Co-Founder	21.3yrs	kr2.54m	33.43% SEK 491.1m
Eugen Steiner	Independent Chairman	6.7yrs	kr621.00k	0.091% SEK 1.3m
Hans Wigzell	Member of Scientific Advisory Board	no data	no data	no data
Konrad Beyreuther	Member of the Scientific Board	no data	no data	no data
Mikael Smedeby	Independent Director	6yrs	kr316.00k	0.031% SEK 453.7k
Ivar Verner	Independent Vice Chairman	14.3yrs	kr406.00k	0.14% SEK 2.0m
Charlotta Ljungqvist	Independent Director	3yrs	kr318.00k	0.0036% SEK 52.6k
Martin Ingelsson	Member of Scientific Board	no data	no data	no data
Staffan Pauli	Member of Scientific Advisory Board	no data	no data	no data
Ken Marek	Member of Scientific Advisory Board	no data	no data	no data
Kaj Blennow	Member of Scientific Advisory Board	no data	no data	no data

10.5yrs

Average Tenure

74yo

Average Age

Experienced Board: B9A's board of directors are seasoned and experienced ( 10.5 years average tenure).

BioArctic Management

Management criteria checks 4/4

Key information

Recent management updates

VP & Head of Research recently sold €242k worth of stock

Vice President of Communications & IR recently sold €147k worth of stock

BioArctic AB (publ) Approves Board Changes

VP & Head of Research recently sold €575k worth of stock

Insider recently bought €21k worth of stock

Independent Director recently sold €291k worth of stock

Recent updates

Full year 2023 earnings released: EPS: kr2.60 (vs kr0.13 loss in FY 2022)

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Full year 2023 earnings released: EPS: kr2.60 (vs kr0.13 loss in FY 2022)

The European Medicines Agency's Scientific Advisory Group (SAG) to Discuss the Marketing Authorisation Application for lecanemab

Third quarter 2023 earnings released: EPS: kr1.42 (vs kr1.55 in 3Q 2022)

BioArctic AB's (publ) Presents New Data on the Investigational Subcutaneous Formulation of LEQEMBI

VP & Head of Research recently sold €242k worth of stock

BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Parkinson's Disease

Second quarter 2023 earnings released: kr1.16 loss per share (vs kr0.52 loss in 2Q 2022)

New minor risk - Share price stability

BioArctic AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Eisai Announces Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Files in South Korea

Now 21% undervalued

Vice President of Communications & IR recently sold €147k worth of stock

BioArctic AB (publ) Approves Board Changes

Eisai Announces Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease

VP & Head of Research recently sold €575k worth of stock

Insider recently bought €21k worth of stock

First quarter 2023 earnings released

Independent Director recently sold €291k worth of stock

BioArctic AB (publ) Announces Board Changes

Full year 2022 earnings released: kr0.13 loss per share (vs kr1.36 loss in FY 2021)

Bioarctic AB's (Publ) Partner Eisai Announces that European Medicines Agency Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

BioArctic AB (publ) Announces Wenche Rolfsen Declines Re-Election to the Board

BioArctic AB (publ) Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI for the Treatment of Alzheimer's Disease

Bioarctic AB's (Publ) Partner Eisai Presents Results from lecanemab Confirmatory Phase 3 Clarity Ad Study

BioArctic AB (publ) Expands Portfolio with Alpha-Synuclein Brain Transporter Project

Insufficient new directors

BioArctic develops New treatment for Gaucher's Disease

Third quarter 2022 earnings released

BioArctic AB (publ) to Report Q3, 2023 Results on Nov 08, 2023

BioArctic AB (publ), Annual General Meeting, Jun 01, 2023

Bioarctic Ab's (Publ) Announces Positive Topline Results for the Large Global Phase 3 Confirmatory Clarity Ad Study in 1,795 Subjects

Bioarctic AB (Publ) Announces Latest Data on Lecanemab Presented At Alzheimer's Association International Conference (Aaic)

Second quarter 2022 earnings released: kr0.52 loss per share (vs kr0.39 loss in 2Q 2021)

Independent Director recently bought €54k worth of stock

First quarter 2022 earnings released

Insufficient new directors

Full year 2021 earnings released: kr1.36 loss per share (vs kr0.78 loss in FY 2020)

Independent Deputy Chairman recently bought €78k worth of stock

Bioarctic AB Announces Executive Changes

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

BioArctic AB (publ) to Report Fiscal Year 2021 Final Results on Mar 31, 2022

DIAN-TU Enrolls First Subject for the Tau Nexgen Study with Lecanemab as Back-Ground Anti-Amyloid Treatment

Bioarctic AB (Publ) Announces Lecanemab Granted Fast Track Designation by the FDA

Third quarter 2021 earnings released

BioArctic AB's partner Eisai Initiates Rolling Submission for the US FDA Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway

Chief Medical Officer recently bought €10k worth of stock

Chief Medical Officer recently bought €10k worth of stock

BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Alzheimer's Disease

Independent Director has left the company

First quarter 2021 earnings released: kr0.33 loss per share (vs kr0.04 profit in 1Q 2020)

Bioarctic and Eisai Present Latest Data Regarding Lecanemab at AD/PD 2021

Bioarctic AB (Publ) and Eisai to Present Data Relating to Its Investigational Anti-Amyloid Beta (Aß) Protofibril Antibody Lecanemab (BAN2401)

BioArctic AB (publ) Announces Board Changes

Full year 2020 earnings released: kr0.78 loss per share (vs kr1.01 profit in FY 2019)

Revenue beats expectations

BioArctic AB (publ) to Report Fiscal Year 2020 Final Results on Mar 31, 2021

BioArctic AB Increases the Number of Participants in Clarity AD Study

New 90-day high: €11.52

BioArctic AB (publ) to Report Nine Months, 2021 Results on Oct 21, 2021

Third quarter earnings released

New 90-day high - €9.02

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure